Roth Capital Reiterates Buy Ahead of Vical (VICL) HSV-2 Data

Roth Capital reiterates a Buy rating and $4.65 price target on Vical (NASDAQ: VICL) ahead of upcoming HSV-2 data. Analyst Debjit Chattopadhyay believes that if the data is positive, that Vical could jump to the head of the market.

Chattopadhyay commented, “The ideal first generation HSV-2 vaccine should not only reduce/prevent symptomatic recurrences but also control asymptomatic viral shedding, providing a public health benefit by decreasing virus transmission to uninfected persons. While competitor Genocea (EV~$191M) is currently in pole position, the upcoming data from Vical (EV~$51M) if positive, could allow it to leapfrog ahead, in our view. Additionally, Vical's partnered CMV asset should start attracting attention as we head into 2016.”

For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.

Shares of Vical closed at $0.98 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• TechnipFMC (FTI) PT Raised to $30 at BTIG
• Amazon.com (AMZN) PT Raised to $215 at UBS